Research/Compounds/Metabolic/Alpha Lipoic Acid
OTC Supplement (US)Oral / IV · Antioxidant

Alpha Lipoic Acid

ALA — Universal Antioxidant & Glucose Sensitizer

Half-life
~30 min (plasma); cellular effects longer
Route
Oral or IV
Typical dose
300–600 mg/day oral; 300-600 mg IV
Reconstitutable
No — oral or pre-mixed IV

What is Alpha Lipoic Acid?

Alpha Lipoic Acid (ALA) is a naturally occurring cofactor for mitochondrial enzyme complexes that functions as a universal antioxidant — being both water and fat-soluble, it protects cellular membranes and aqueous compartments simultaneously. It regenerates vitamins C and E and glutathione, improves insulin sensitivity, chelates heavy metals, and has demonstrated neuroprotective properties. It is used clinically for diabetic neuropathy in Germany (as a prescription drug) and globally as a supplement.

ALA is reduced to DHLA (dihydrolipoic acid) inside cells, creating a potent antioxidant pair that scavenges ROS in both lipid and aqueous environments. DHLA regenerates oxidized glutathione, vitamin C, and vitamin E back to their active forms — amplifying the entire antioxidant network. ALA also activates AMPK (improving insulin sensitivity and metabolic rate), inhibits NF-kB (anti-inflammatory), and chelates heavy metals like mercury and lead.

Research Evidence

GoldDiabetic Neuropathy

Multiple Phase 3 RCTs demonstrate IV and oral ALA significantly reduces symptoms of diabetic peripheral neuropathy. Approved as a drug for this indication in Germany.

SilverInsulin Sensitivity

Controlled trials show ALA improves insulin-mediated glucose uptake and reduces HbA1c in type 2 diabetics through AMPK activation.

SilverNeuroprotection

Human and animal studies show ALA protects neurons from oxidative damage. Studied for Alzheimer's, Parkinson's, and cognitive decline prevention.

Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary

Dosing Protocols

Standard oral dose
300–600 mg/day
Take away from meals (food reduces absorption). R-ALA (the natural form) is more bioavailable than racemic ALA and effective at lower doses (100-300 mg).
IV dose
300–600 mg in 100ml saline
IV ALA achieves much higher peak plasma levels than oral. Used in clinical settings for neuropathy treatment.
R-ALA vs racemic
R-form preferred
ALA sold as a supplement is often racemic (R+S mixture). R-ALA (the biologically active form) is more potent and better tolerated at lower doses.

Reconstitution / Preparation

This compound does not require reconstitution — it is available as an oral or pre-mixed formulation.

Frequently Asked Questions

Should I take ALA with or without food?

Without food — ALA absorption is significantly reduced when taken with meals. Take ALA 30-60 minutes before eating for maximum absorption. The R-form (R-ALA) absorbs better than racemic ALA regardless of food timing.

Does Alpha Lipoic Acid chelate mercury?

Yes. ALA chelates mercury and other heavy metals, which is both a potential benefit (detoxification) and a concern. If mercury amalgam fillings are present or recent amalgam removal has occurred, ALA supplementation should be avoided until the amalgams are removed and the body has had time to clear initial mercury load — ALA can redistribute mercury to the brain in these circumstances.

References

  1. [1]Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care. 2006;29(11):2365-2370.
  2. [2]Konrad T, Vicini P, Kusterer K, et al. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999;22(2):280-287.
Disclaimer: This profile is for informational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before using any compound.

This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.

Share this article